CJC 1295 Doses, Administration, Cycles, Side Effects
CJC 1295 Doses, Administration, Cycles, Side Effects
CJC – 1295
CJC-1295 is a synthetic peptide that mimics growth hormone releasing factor (GRF). It stimulates the pituitary gland to produce and release more endogenous growth hormone, thereby promoting muscle growth, fat loss, improved recovery, and overall anabolic effects. The peptide has gained popularity among athletes, bodybuilders, and individuals seeking anti-aging benefits.
Overview and History of Modified GRF 1-29 (CJC-1295 without DAC)
Modified GRF 1-29 refers to the first 29 amino acids of growth hormone releasing hormone (GHRH). The original peptide was discovered in the early 1990s as a potential therapeutic for growth hormone deficiency. Researchers noticed that the peptide’s half-life was short, limiting its clinical utility. Subsequent modifications led to the creation of CJC-1295 with and without a drug affinity complex (DAC). The version without DAC retains the core GRF sequence but lacks the PEGylated attachment that prolongs circulation time.
The non-DAC form was developed to provide a more natural pharmacokinetic profile while still boosting growth hormone secretion. It allows for tighter control over dosing intervals and is often preferred by those who wish to avoid the long-lasting effects of the DAC variant.
Chemical Characteristics of Modified GRF 1-29 (CJC-1295 without DAC)
The peptide is composed of a chain of 29 amino acids, with a molecular weight around 3,200 Daltons. Its sequence is:
H–Glu–Thr–Lys–Ser–Pro–Arg–His–Ile–Val–Ala–Leu–Asp–Leu–Asn–Gln–Gly–Tyr–Cys–Gly–Pro–Met–Phe–Thr–Gly–Arg–Trp–His–Lys–Glu–OH
Key chemical features include:
Hydrophilic and hydrophobic residues that allow the peptide to fold into a stable conformation.
CJC 1295 Doses, Administration, Cycles, Side Effects
CJC – 1295
CJC-1295 is a synthetic peptide that mimics growth hormone releasing factor (GRF). It stimulates the pituitary gland to produce and release more endogenous growth hormone, thereby promoting muscle growth, fat loss, improved recovery, and overall anabolic effects. The peptide has gained popularity among athletes, bodybuilders, and individuals seeking anti-aging benefits.
Overview and History of Modified GRF 1-29 (CJC-1295 without DAC)
Modified GRF 1-29 refers to the first 29 amino acids of growth hormone releasing hormone (GHRH). The original peptide was discovered in the early 1990s as a potential therapeutic for growth hormone deficiency. Researchers noticed that the peptide’s half-life was short, limiting its clinical utility. Subsequent modifications led to the creation of CJC-1295 with and without a drug affinity complex (DAC). The version without DAC retains the core GRF sequence but lacks the PEGylated attachment that prolongs circulation time.
The non-DAC form was developed to provide a more natural pharmacokinetic profile while still boosting growth hormone secretion. It allows for tighter control over dosing intervals and is often preferred by those who wish to avoid the long-lasting effects of the DAC variant.
Chemical Characteristics of Modified GRF 1-29 (CJC-1295 without DAC)
The peptide is composed of a chain of 29 amino acids, with a molecular weight around 3,200 Daltons. Its sequence is:
H–Glu–Thr–Lys–Ser–Pro–Arg–His–Ile–Val–Ala–Leu–Asp–Leu–Asn–Gln–Gly–Tyr–Cys–Gly–Pro–Met–Phe–Thr–Gly–Arg–Trp–His–Lys–Glu–OH
Key chemical features include:
Hydrophilic and hydrophobic residues that allow the peptide to fold into a stable conformation.